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The purpose of the present study was to establish a pharmacokinetic/pharmacodynamic 
(PK/PD) modeling approach for the dosage schedule design and decreasing the emergence 
of drug-resistant bacteria. The minimal inhibitory concentration (MIC) of 929 Escherichia 
coli isolates from broilers to enrofloxacin and ciprofloxacin was determined following CLSI 
guidance. The MIC50 was calculated as the populational PD parameter for enrofloxacin 
against E. coli in broilers. The 101 E. coli strains with MIC closest to the MIC50 (0.05 μg/
mL) were submitted for serotype identification. The 13 E. coli strains with O and K serotype 
were further utilized for determining pathogencity in mice. Of all the strains tested, the E. 
coli designated strain Anhui 112 was selected for establishing the disease model and PK/
PD study. The PKs of enrofloxacin after oral administration at the dose of 10 mg/kg body 
weights (BW) in healthy and infected broilers was evaluated with high-performance liquid 
chromatography (HPLC) method. For intestinal contents after oral administration, the peak 
concentration (Cmax), the time when the maximum concentration reached (Tmax), and the 
area under the concentration-time curve (AUC) were 21.69–31.69 μg/mL, 1.13–1.23 h, 
and 228.97–444.86 μg h/mL, respectively. The MIC and minimal bactericidal concentration 
(MBC) of enrofloxacin against E. coli (Anhui 112) in Mueller–Hinton (MH) broth and intestinal 
contents were determined to be similar, 0.25 and 0.5 μg/mL respectively. In this study, 
the sum of concentrations of enrofloxacin and its metabolite (ciprofloxacin) was used for 
the PK/PD integration and modeling. The ex vivo growth inhibition data were fitted to the 
sigmoid Emax (Hill) equation to provide values for intestinal contents of 24 h area under con-
centration-time curve/MIC ratios (AUC0–24 h/MIC) producing, bacteriostasis (624.94 h), 
bactericidal activity (1065.93 h) and bacterial eradication (1343.81 h). PK/PD modeling 
was established to simulate the efficacy of enrofloxacin for different dosage regimens. By 
model validation, the protection rate was 83.3%, demonstrating that the dosage regimen 
of 11.9 mg/kg BW every 24 h during 3 days provided great therapeutic significance. In 
summary, the purpose of the present study was to first design a dosage regimen for the 
treatment E. coli in broilers by enrofloxacin using PK/PD integrate model and confirm that 
this dosage regimen presents less risk for emergence of floroquinolone resistance.
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inTrODUcTiOn
Antimicrobial resistance is a principal threat to both animals 
and humans, the main reason for the increasing bacterial resist-
ance is the overuse and misuse of antibiotics. Optimizing the 
dosage schedules is essential for achieving clinical cures and 
minimizing the emergence of antimicrobial drug resistance (1, 
2). Currently, the optimal dose regimen should be calculated 
according to the relationship between pharmacokinetics (PKs) 
and pharmacodynamics (PD) (3). PK/PD modeling can reflect 
the relationship between the drug, the bacteria, and the animals. 
It has been demonstrated in many studies that the integration and 
modeling of the relationship between PK and PD can quantify the 
potency and efficacy of antimicrobials against target pathogens 
and provide a basis for the dose optimization (4–7).
PK/PD modeling can be used to evaluate the clinical 
efficacy of antimicrobial agents (4, 8). The most widely used 
PK parameters are the area under the plasma concentration-
time curve (AUC) and the maximum plasma concentration 
(Cmax). The most commonly used PD parameters include 
minimal inhibitory concentration (MIC) and time-kill curve. 
The integration of PK and PD establishes a mathematical and 
theoretical link between them. The three PK/PD parameters are 
AUC/MIC ratio, Cmax/MIC ratio, and the percentage of a 24-h 
time period that the unbound drug concentration exceeds the 
MIC (T > MIC) (7, 9, 10). Fluoroquinolones are classified as 
typical concentration-dependent drugs, the initially reported 
AUC/MIC and Cmax/MIC are better predictors than T > MIC 
for the antibacterial effect (11, 12). Therefore, it is very impor-
tant to determine the AUC/MIC value of enrofloxacin against 
Escherichia coli in broilers.
Escherichia coli is a Gram-negative facultative anaerobe, 
it is a frequent cause of septicemia, Enterocolitis, and diffuse 
peritonitis. Colibacillosis has caused great economic losses to 
the poultry industry and commonly fluoroquinolones are used 
for the treatment (13–15). At the same time, the serious abuse of 
fluoroquinolones in clinical settings has been implicated in treat-
ment dissatisfaction or even treatment failure, it also contributes 
to the emergence of bacterial antibiotic resistance.
Pharmacokinetics of enrofloxacin has already been studied 
in many species, including calves, turkeys, horses, goats, sheep 
and pigs (16–21); however, studies on the PK of enrofloxacin in 
infected animals are quite few even though the PK parameters in 
infected animals are more close to the clinical conditions (22). 
The metabolism of enrofloxacin to ciprofloxacin in broilers is 
limited to 5 and 10% (23, 24). There is some research on the PK 
of enrofloxacin in intestinal contents (25, 26), but limited data 
are available regarding the PK/PD in broiler intestinal contents.
The objectives of the study were to: (1) investigate the popula-
tion MIC and select clinical strains with higher pathogenicity 
for establishing bacterial infected model, (2) determine the PK 
of enrofloxacin orally administrated in healthy and infected 
broilers, (3) determine the PD of enrofloxacin against clinical E. 
coli pathogenic strains, (4) use the PK/PD model to optimize the 
dosage regimen of enrofloxacin against colibacillosis in broilers, 
and (5) validate the model to verify the clinical efficacy of the 
resulting dosage regimen.
MaTerials anD MeThODs
animals
Broilers
Thirty-day-old healthy KeBao broilers obtained from a commer-
cial poultry farm in Jiang Xia were utilized for this experiment 
(n = 160), the broilers were mixed sex (50:50) with weights rang-
ing between 0.9 and 1.2 kg. The broilers were randomly distrib-
uted into two treatment groups (n = 80/treatment group) Group 
1 served as the non-infected healthy controls animals and Group 
2 the E. coli-infected disease animals. All broilers were allowed 
7 days for acclimation before the experiments began. All broilers 
were housed in a climate control environment under identical 
conditions with standard commercial diet and water supplied.
Mice
Four-week-old healthy Kunming mice (SPF grand, kw: 18 ± 2 g, 
n = 120, half male and half female) were obtained from the Center 
of Experimental Animal of Hubei, and housed in SPF animal 
room in our lab [Licence# SCXK(E) 2008-0005].
All experimental procedures in this study were performed 
according to the guidelines of the committee on the use and care 
of the laboratory animals in Hubei province, China. The study 
was approved by the Animal Care Center, Hubei Science and 
Technology Agency in China (SYXK 2013–0044). All the animals 
were monitored throughout the study for any signs of adverse 
effects.
chemicals and reagents
The Enrofloxacin reference standard (98% purity) and 
Ciprofloxacin Hydrochloride reference standard (95% purity) 
were purchased from Dr. Ehrenstorfer (Augsburg, Germany). The 
Enrofloxacin API (98% purity) used for PKs study was acquired 
from a local distributor (Wuhan Midland Chemical Co., Ltd.), 
the supplied powder was dissolved in 5% sodium carboxymethyl 
cellulose (CMC) to allow for oral administration. Acetonitrile 
(ACN), formic acid and methanol (MeOH) were provided by 
TEDIA (USA). All chemicals used in this experiment were ana-
lytical grade or higher and dissolved or diluted using de-ionized 
water (Milli-Q Millipore Corp.).
Bacteria
The clinical E. coli pathogenic strain designated Anhui112 was 
previously isolated from broiler chickens with colibacillosis. 
This strain was used for the PD study and the E. coli infection 
model. The commonly used quality control standard E. coli strain 
ATCC 25922 was purchased from Chinese Veterinary Culture 
Collection. All strains were stored at −80°C until use. Before 
each experiment, these bacteria cultures were sub-cultured on 
Mueller–Hinton agar and incubated at 37°C for 18–24 h.
Determining the Mic of enrofloxacin 
against clinical E. coli isolates
A total of 929 clinical isolates collected from five provinces in 
central China and stored in the laboratory were studied in this 
experiment. The determination of MIC for enrofloxacin and 
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ciprofloxacin against all clinical E. coli strains was determined by 
the microdilution broth method, using the E. coli ATCC 25922 as 
the experimental control strain and following CLSI (Clinical and 
Laboratory Standards Institute, 2009, M07-A9) protocol. MICs 
were found to be in the range between 0.04 and 64 μg/mL. Using 
SPSS 16.0, the 50% minimum inhibitory concentration (MIC50) 
0.50 μg/mL and 90% minimum inhibitory concentration (MIC90) 
16.21 μg/mL were determined to represent the population PD of 
enrofloxacin against clinical E. coli.
serotype identification
The clinical E. coli strains, approximately 101 strains, with the 
MIC closest to MIC50, were further tested for determining which 
strains were serotype O or K positive. The O and K anti-serum 
was purchased from China Institute of Veterinary Drug Control 
(IVDC). Serotype was determined by traditional slide agglutina-
tion test using the commercialized antigen diagnostic serum 
following previously published methods (27).
Pathogenicity experiment on Mice
The strains previously identified as either serotype O or K 
(n = 13) were used in a pathogenicity experiment on mice. Each 
of the 13 strains were administered intra-peritoneally (200 ul) to 
a separate group of mice (n = 9/group) at three different doses 
[1 ×  l08, 1 ×  l07, and1 ×  l06 colony forming units (CFU)/mL, 
n = 3/dose] to establish the infection model; additionally there 
was a none treated control group for a total of 14 groups. All mice 
were closely observed for the first 6 h and then once every 2 h 
for the remainder of the day. Any behavioral changes observed 
were noted and recorded by time and group. At the conclusion 
of this experiment, the data were analyzed and the most virulent 
strain was selected to conduct PD study and establish the E. coli 
infection model.
establishing E. coli infection Model in 
Broilers
After a 7-day acclimation period, 160 broilers were randomly 
selected and distributed into one of two experimental groups 
(n = 80/group). Each of the 80 broilers in the infection group 
was inoculated by oral gavage with 8  mL of E. coli culture 
(previously determined to be the most virulent) containing 
1.2 ×  109 CFU/mL. Birds were observed after inoculation for 
clinical symptoms and pathological changes. After 12 h, sterile 
tissue (liver) samples were collected by necropsy from dead 
broilers and cultured to confirm that mortality was caused by 
the inoculated strain.
Pharmacokinetic experiment
After a 7-day acclimation period, 160 broilers were randomly 
divided into two groups (n =  80/group): the E. coli infection 
model and healthy control model. On the morning of the eighth 
day, enrofloxacin was orally administered at a dose of 10 mg/kg to 
all broilers. At the following time points after oral administration 
of enrofloxacin: 0, 0.25, 0.5, 0.75, 1, 1.5, 2, 3, 4, 8, 12, 24, and 
48 h, six broilers per group were humanly killed to collect blood 
samples (2 mL) and intestinal contents (2 mL).
Blood samples collected with anticoagulant were centrifuged 
for 10  min at 3000  rpms to obtain plasma. The plasma was 
removed to a clean sterile tube and stored at −20°C until analysis. 
At a later time point, 1 mL of plasma was added to a 10 mL tube, 
2 mL of ACN was then added to precipitate proteins. The tube was 
vortexed for 2 min and centrifuged at 4000 rpms for 10 min, the 
aqueous phase was transferred to a clean tube and dried under 
nitrogen. One milliliter of 14% ACN was used to reconstitute the 
dried pellet. The sample was filtered through a 0.22 μm mem-
brane into the high-performance liquid chromatography (HPLC) 
detection vial.
Intestinal content (1  g) was homogenized for 1  min in a 
50 mL tube, 2 mL of 0.5 M EDTA (pH 7.0) was then added to the 
homogenate followed by 15 mL of dichloromethane. The mixture 
was vortex-mixed for 1  min and centrifuged at 5000  rpms for 
5  min. This extraction procedure was repeated twice and then 
dried under nitrogen. The dried pellet was reconstituted using 
1 mL 12% ACN then centrifuged at 12,000 rpm for 5 min before 
analysis. The supernatant was removed and filtered through a 
0.22 μm membrane, into the HPLC detection vial.
The concentration of enrofloxacin and ciprofloxacin in plasma 
and intestinal content were determined by the HPLC method 
with UV (UltraViolet) detector (28) under the following condi-
tions: UV detection 278 nm, column temperature 30°C, mobile 
phase water with 0.1% formic acid and ACN, and sample size 
40 μL injected into the HPLC (Waters 2695) system with a flow 
rate 1 mL/min.
The concentration–time data variables and Pharmacokinetics 
parameters of enrofloxacin and ciprofloxacin were derived from 
the Winnonlin program (version 5.2.1, Pharsight Corporation, 
Mountain View, CA, USA). The plasma concentration deter-
mined data were analyzed with compartmental method. The 
linear trapezoidal rule was used to calculate the AUC.
Determination of Mic, MBc, MPc, 
and Pae
The MIC of Anhui112 was determined using the previous detailed 
method.
The minimal bactericidal concentration (MBC) was deter-
mined after MIC reading, 100 μL bacteria suspension from each 
well of the 96 microwell plate was spread on MH agar plates and 
incubated at 37°C for 24 h for bacterial counting. MBC in broth 
and intestine were determined as the lowest concentration at 
which bacteria numbers were reduced by 99.9%.
The mutant prevention concentration (MPC) of enrofloxacin 
was determined using the agar method (29). The 1010 CFU/mL E. 
coli strains were inoculated on the agar plates containing serial 
concentration of enrofloxacin (1 ×  MIC, 2 ×  MIC, 4 ×  MIC, 
8 × MIC, 16 × MIC, and 32 × MIC) and cultured at 37°C for 72 h. 
The MPC was defined as the lowest concentration of enrofloxacin 
on agar plates without bacterial growth.
For the post-antibiotic effect (PAE) determination, the bacterial 
was exposed to three different concentrations (1 × MIC, 2 × MIC 
and 4 × MIC) of enrofloxacin for 1 or 2 h. The media containing 
enrofloxacin was removed by centrifuge at 12000 × g for 5 min. 
The bacterial was re-grew in fresh media without enrofloxacin for 
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another 24 h. The bacterial numbers were determined at differ-
ent time points. The PAE was the time difference (in hours) for 
antimicrobial-treated bacterial to increase in number by 1 log10 
minus the same determination for non-treated cultures of the 
same test bacterial.
Drawing In vitro and Ex Vivo Bacterial 
Killing curves
In vitro bacterial killing curves were determined in MH broth. 
Different concentrations of enrofloxacin: 1/2MIC, 1MIC, 2MIC, 
4MIC, 8MIC, 16MIC, and 32MIC were prepared in MH broth, 
the tubes were then inoculated with E. coli Anhui112 (106CFU/
mL) and incubated at 37°C. The bacterial count (CFU/mL) was 
determined for each tube after 1, 2, 4, 6, 8,12, and 24 h of incuba-
tion. Briefly, 100 μL culture was obtained for each time point, 
serially diluted with sterile saline plated and the colonies counted 
the next morning. The limit of detection was 10 CFU/mL. Each 
concentration test was performed in triplicate.
The Ex vivo bacterial killing curves were determined in intesti-
nal content samples obtained from broilers at different time points 
after oral administration with enrofloxacin following the method 
as described earlier for the in vitro study. The tubes containing 
bacterial culture and intestinal content were incubated at 37°C 
and then viable bacteria counts were determined at 1, 2, 4, 8, 12, 
and 24 h time points. The limit of detection was 10 CFU/mL. Each 
concentration test was performed in triplicate.
PK and PD integration and Modeling
All PK parameters were calculated by WinNonlin 5.2 software, 
including T > MIC, Cmax, T1/2, AUC, etc. PK analysis was performed 
with one-compartmental model. Using in vitro MIC and in vivo PK 
parameters, the surrogate parameters (Cmax/MIC, AUC/MIC, and 
T > MIC) of intestinal content were determined after oral admin-
istration of enrofloxacin. The relationship between the ex vivo 
AUC24h/MIC ratio and the bacterial count after 24 h of incubation 
in intestinal content was determined by using the sigmoid inhibi-
tory Emax model. This model is described by the following equation:
 
E E E E C
C EC
N
N N= −
− ⋅
+max
max( )0
50  
In which, E is the antibacterial effect measured as the change 
in the bacterial count (log10CFU/mL) in the serum sample after 
24 h of incubation compared to the initial log10CFU/mL; Emax is 
the maximum antibacterial effect determined as the difference 
of log10CFU/mL in sample incubated between 0 and 24 h time 
point; E0 is the log10 difference of bacterial count in the control 
sample containing tylosin after 24  h of incubation; EC50 is the 
AUC/MIC producing 50% of the maximum antibacterial effect; C 
is the AUC/MIC in the effect compartment (the ex vivo site, that 
is serum); and N is the Hill coefficient, which describes the 
steepness of the AUC/MIC-effect curve.
To investigate the effect of different dosage regimens, the PD 
model describing bacterial growth rate in function of enrofloxacin 
concentration was combined with the PK model and simulations 
were performed with mlxplore software (version-1.1.0, Lixoft, 
Orsay, France).
Dosage regiment
Four levels of antibacterial effect of enrofloxacin were quanti-
fied from the sigmoid Emax equation by determining AUC/MIC 
required for bacteriostatic action (no change in bacterial count 
after 24 h of incubation, E = 0), a 50% reduction of the bacte-
rial count, bactericidal action (a 99.9% decrease in the bacterial 
count, E = 3), and bacterial elimination (the lowest AUC/MIC 
that produce a 99.99% reduction in the count, E =  4) in each 
intestinal content. The calculation of potential optimal dosage 
can use the following equation:
 
X d AUC MIC
AUC MIC
= × ex vivo tested
in vivo target
/
/
 
where d is the projected dosage (mg/kg), 10 mg/kg was used in this 
study. The value of the ex vivo AUC24/MIC obtained from intesti-
nal content represents bacteriostatic activity, bactericidal activity, 
and elimination of organisms, respectively. The in  vivo AUC is 
obtained from the PK using MIC50 as the target MIC in this study.
risk assessment of E. coli resistance
The concentration of enrofloxacin was adjusted to 0, 0.125, 0.25, 
0.5, 1, 2, 4, and 8 μg/mL with MH broth and 109 CFU/mL of 
bacteria were added to each tube; after 2, 4, 6, 8,12, 18, 24,36, 
and 48 h of incubation 100 μL was removed from each tube and 
plated on MH agar plates which contained 1 μg/mL enrofloxacin. 
Any plate containing 100 CFUs or less were not considered to be 
a drug induced mutation.
Model Validation of the  
Dosage regiment
In order to verify the clinical efficacy of the resulting suggested 
dosage regimen, 24 broilers with artificially induced colibacillosis 
were divided into two groups randomly (n =  12/group), and 
administered saline or antibiotic at a previously determined dos-
age regimen. Clinical symptoms and pathological changes were 
observed and recorded for 48 h.
ethical statement
All the experimental procedures in this study were performed 
according to the guidelines of the laboratory care and use com-
mittee in Hubei province, China. The study was approved by 
Animal Ethics Committee of Huazhong Agricultural University 
and the Animal Care Center, Hubei Science and Technology 
Agency in China (SYXK 2013-0044). All the animals were 
monitored throughout the study for any adverse effect signs. This 
experiment is in line with national regulations regarding animal 
welfare ethics. Ethical approval number is hzauch 2014-002.
resUlTs
Mic Distribution of the clinical E. coli 
strains
The MIC distribution of the 929 E. coli strains to enrofloxacin and 
ciprofloxacin is shown in Figure 1. The MIC for enrofloxacin and 
ciprofloxacin exhibited a trimodel distribution, indicating that 
               
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FigUre 1 | enrofloxacin and ciprofloxacin Mic distribution of 929 Escherichia coli strains isolated from broiler farms. The X-axis was the MIC values 
and Y-axis was the strain number in each MIC value.
TaBle 1 | Mic and serotype distribution of clinical isolates (microgram per milliliter).
Bacteria Mic O K Death/totala
1 × l08 cFUb 1 × l07 cFUb 1 × l06 cFUb
Zhengzhou379 0.25 O75 987P 1/3 0/3 0/3
Zhengzhou384 0.125 O40 K99 1/3 0/3 0/3
Zhengzhou389 0.125 O9 K88 0/3 0/3 0/3
Zhengyang113 0.125 O18 K99 0/3 0/3 0/3
Jingzhou9 0.25 O93 K88 3/3 2/3 1/3
Jingzhou77 0.06 O138 K88 2/3 0/3 0/3
Xinzhou18 0.25 O139 K99 2/3 1/3 0/3
Xinzhou52 0.25 O101 K88 2/3 1/3 1/3
Xinzhou54 0.25 O80 K99 1/3 0/3 0/3
Xinzhou100 0.25 O40 K99 1/3 0/3 0/3
Anhui112 0.25 O2 K88 3/3 3/3 2/3
Zhengzhou16 0.25 O18 K88 1/3 0/3 0/3
Zhengyang18 0.25 O20 K88 0/3 0/3 0/3
Control group 0/3 0/3 0/3
aRepresents the death number of mice and the ratio of the total.
bNumber of colonies to each mice by intraperitoneal injection.
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there may be some resistant strains. The MIC50 and MIC90 for 
enrofloxacin were 0.05 and 16 μg/mL, respectively.
serotype and Pathogenicity of the 
selected E. coli strains
Approximately, 101 E. coli strains; which were closest to MIC50 
(0.05  μg/mL) were selected for further analysis by serotyping 
specifically selecting for serotypes O and K. Only 13 E. coli 
isolates were identified as O or K serotype. And these 13 E. coli 
isolates were used for a pathogenicity experiment in mice. From 
the results (Table 1), we were able to identify the most virulent 
strain, Anhui 112. Therefore, E. coli Anhui 112 was selected to 
conduct the PD study and to establish the infection model.
E. coli infection Model
Using E. coli Anhui 112, we were able to successfully reproduce 
an E. coli infection model in commercial broiler chickens, within 
12  h after challenge with Anhui 112, broilers exhibited typical 
clinical signs of colibacillosis, such as the elevated temperature, 
loss of appetite, and white loose droppings. Lesions examined by 
necropsy showed a layer of white cellulose pseudo-membranous 
covering the surface of the liver and heart consistent with classical 
colibacillosis, clearly seen in Figure 2.
Pharmacokinetics of enrofloxacin
The intestinal content concentrations of enrofloxacin and 
ciprofloxacin were determined after oral administration of the 
antibiotics to the healthy and infected broilers (Figure 3). After 
oral administration, plasma and intestinal content concentration 
of enrofloxacin was best fitted with a one-compartment model, 
all PK parameters were calculated by WinNonlin 5.2. The PK 
parameters of enrofloxacin in intestinal content are illustrated 
in Table 2. In the healthy model, the AUC, Cmax, and Tmax were 
228.97 μg mL−1 h, 21.69 μg mL−1, and 1.23 h, respectively. In the 
FigUre 2 | Broilers infected with E. coli anhui112 strains. After 
infection by E.coli, the broilers had serious Diarrhea (a) and liver lesions (B).
FigUre 3 | concentration-time curves of enrofloxacin and ciprofloxacin in the intestinal contents from healthy chicken (a) and bacterial infected 
chicken (B). The X-axis was the time point and Y-axis was the drug concentrations. The ciprofloxacin was the metabolite of enrofloxacin in chicken intestinal 
contents.
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infected model the AUC, Cmax, and Tmax were 444.86 μg mL−1 h, 
31.69 μg mL−1, and 1.13 h, respectively.
Mic, MBc, MPc, and Pae of enr and cip 
against anhui 112
The MIC and MBC of enrofloxacin in MH broth and intestinal 
contents were similar 0.25 and 0.5 μg/mL, respectively. The MPC 
value of enrofloxacin and ciprofloxacin against Anhui 112 were 7 
and 0.625 μg/mL, respectively. The PAE showed strong concentra-
tion-dependent tendencies. These results are presented in Table 3.
In vitro and Ex Vivo antimicrobial activity
According to the MIC values, a series of varying concentrations 
of enrofloxacin and ciprofloxacin were prepared in MH broth 
(1/2–32MIC) to ascertain the in vitro bactericidal curve against 
Anhui 112 (Figure  4). The curves are characteristically typical 
for concentration-dependent antibiotic activity. When exposed 
to the higher concentration (≥1 × MIC) of enrofloxacin or cipro-
floxacin for 6 h, the bacterial CFUs were significantly decreased 
to undetectable level (<30 CFU). When the bacterial was exposed 
to 1 × MIC of the two drugs, the growth of bacterial was inhibited 
at the first 8 h but was rebounded during 8–24 h.
The results showed that in an ex vivo environment enrofloxacin 
is typically concentration dependent (Figure 5), consistent with 
TaBle 2 | Pharmacokinetic parameters of enrofloxacin and ciprofloxacin in intestinal contents after oral administration of enrofloxacin at 10 mg/kg BW 
to broilers.
PK parameters (units) healthy model infected model
enr ciP enr + ciP enr ciP enr + ciP
AUC (μg h/mL) 206.30 18.63 228.97 406.74 31.39 444.86
Tmax (h) 1.18 5.50 1.23 1.06 6.09 1.13
Cmax (μg mL−1) 21.07 1.11 21.69 30.88 1.46 31.69
V/F (mL/kg) 413.02 4967.17 403.45 296.59 4392.84 289.02
Cl/F (mL/h/kg) 48.47 536.84 43.67 24.58 318.52 22.48
Ka (h−1) 2.79 0.28 2.72 3.66 0.31 3.43
Ke (h−1) 0.12 0.11 0.11 0.08 0.07 0.08
T1/2e (h) 5.91 6.41 6.40 8.36 9.56 8.91
T > MIC 39.29 30.08 42.79 49.89 43.59 49.95
TaBle 3 | antibacterial activity of enrofloxacin and ciprofloxacin against E. coli in vitro.
Drug Mic (μg/ml) MBc (μg/ml) MPc (μg/ml) Pae
Broths and intestinal Broths and intestinal Broths
concentration (μg/ml) expose (1 h) expose (2 h)
ENR 0.25 0.5 7 MIC (0.25) 0.2 h 0.4 h
2 MIC (0.5) 0.8 h 1.2 h
4 MIC (1) 1.4 h 1.6 h
CIP 0.125 0.25 0.625 MIC (0.125) 0.2 h 0.4 h
2 MIC (0.25) 0.8 h 1.4 h
4 MIC (0.5) 1.5 h 1.6 h
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the in vitro antibacterial curve. In the high concentration group, 
the enumerated CFUs changed significantly. After 4-h and 8-h 
cultures, there were no detectable bacteria in infected broilers.
PK/PD integration and analysis
The integration of in vivo PK and in vitro PD data of enrofloxacin 
in intestinal contents showed AUC/MIC50 ratios for healthy and 
infected broilers to be 455.20 and 884.41  h, respectively. The 
Cmax/MIC ratios were 43.38 and 63.38, respectively. Sigmoid Emax 
model was utilized to simulate the relationships between Cmax/
MIC, AUC/MIC, and ex vivo antimicrobial efficacy.
Dosage Determination
According to the dosage equation X d AUC MIC
AUC MIC
= × ex vivo tested
in vivo target
/
/
, the 
optimal dose X (mg/kg/d) was calculated. The d was the projected 
dosage (10 mg/kg) in this study. The AUCin vivo/MICtarget(0.5 μg/
mL, the MIC50 of enrofloxacin against clinical strains) for infected 
broilers were 455.20 and 884.41 h, respectively. See Table 4 of ex 
vivo parameters, when E = 0, the AUCex vivo/MICtest (0.25 μg/mL, 
MIC of enrofloxacin to E. coli Anhui112) for healthy and infected 
broiler were 258.73 and 624.94 h, respectively. When E = −3, the 
AUCex vivo/MICtest for healthy and infected broiler were 451.35 
and 1065.93 h, respectively. When E = −4, the AUCex vivo/MICtest 
for healthy and infected broiler were 567.39 and 1343.81  h, 
respectively. Therefore, see Table  5, the doses calculated for 
bacteriostatic action (E = 0) in healthy and infected broilers were 
5.6 and 7 mg/kg BW. The doses calculated for bactericidal action 
(E = −3) in healthy and infected broilers were 9.8 and 11.9 mg/kg 
BW. The calculated for bacterial eradication (E = −4) in healthy 
and infected broilers were 12.4 and 15.1 mg/kg BW. Ultimately, 
for treatment E.coli infection in broiler, the preventive, therapeu-
tic, and bacterial eradication dose of enrofloxacin were chosen as 
7.0, 11.9, and 15.1 mg/kg BW.
Due to intensive broiler rearing practices, a mixed feeding 
dosage regimen was also calculated in our study. According to 
the groups feeding dosing formula D = d × n/W, for 21-day-old 
broilers, the value of W is approximately 120 g/kg/d, n is the daily 
dosing frequency and D is group mixed feeding dosage. When the 
MIC50 against clinical strains is 0.5 μg/mL, the optimum dose is 
99 mg/kg for mixed feeding.
Using the PK/PD model with the PD parameters derived from 
ex vivo antimicrobial activity, three selected doses (7.0, 11.9, 
15.1 mg/kg BW) were separately simulated. As shown in Figure 6, 
after single dose treatment for 24 h, higher dose (11.9 and 15.1 mg/
kg BW) played bactericidal or eradication action during 0–18 h, 
but the bacteria rebound phenomenon was occurred under the 
lower dose (7 mg/kg BW) treatment. As shown in Figure 7, after 
daily-treatment of the three selected doses (7.0, 11.9, 15.1 mg/kg 
BW) for 3 days, the higher doses (11.9, 15.1 mg/kg BW) exhibited 
great bactericidal and eradication action; however, the bacterial 
was not inhibited under lower 3-day treatment of lower dose 
(7 mg/kg BW).
assessment of Bacterial resistance
Results in Table  6 show that when the drug concentration is 
higher than 8  μg/mL, drug-resistant strains do not appear; 
FigUre 4 | The in vitro kill bacteria curve of enrofloxacin (a) and ciprofloxacin (B) against E.coli anhui112. The X-axis was the time point during the 
24-hours incubation and Y-axis was the bacterial number under exposure to deferent concentration (1/4 × MIC, 1/2 × MIC….0.32 × MIC) of drug.
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however, when the drug concentration is 2–4 μg/mL, drug resist-
ance strains appear after 36 h. Resistance strains are most easily 
achieved when the drug concentrations are between 0.25 and 
1 μg/mL after 24 h. Similar results were observed between the 
blank samples (without drug) and the samples whose concentra-
tion is 0.125 μg/mL or less. The data indicate resistant strains 
generally appear after 24  h; therefore, the dosing interval was 
chosen to be 24 h.
Model Validation
Results show that the protection rate of control group was 8.3%, 
while the protection rate of the experiment group was 83.3%. 
These data indicate that the dosage regimen chosen has a signifi-
cant therapeutic effect, suitable for clinical treatment (Table 7).
DiscUssiOn
In this investigation, enrofloxacin was orally administered 
at a clinical recommended effective dose (10  mg/kg BW) in 
healthy and infected broilers. Although the PK of enrofloxacin 
in the serum of goats, pigs, calves, horses, and sheep after 
administration has already been investigated many times 
(16–19, 30), reports concerning the PK in the intestinal contents 
are quite few. In this study, enrofloxacin concentrations in intes-
tinal contents were calculated to be 0.35~28.05 μg/mL. These 
concentrations were much higher than the concentration of 
enrofloxacin in plasma of healthy broilers, which were between 
0.04 and 2.01 μg/mL. According to Slana et al. (24) enrofloxacin 
concentrations in manure samples, after 15  mg/kg BW orally 
administered, ranged between 39.2 and 55.0 μg/g. Moraru et al. 
(31) detected enrofloxacin concentrations in excreta samples 
ranged between 40.5 and 50.7 μg/g after 3 days orally treatment 
with 10  mg enrofloxacin/kg BW. Devreese et  al. (26) found 
enrofloxacin concentrations in cloacal samples ranged between 
20.1 and 55.7 μg/g after orally treatment of 10 mg enrofloxacin/
kg BW. In this study, we found the enrofloxacin concentrations 
in the intestinal contents were significantly less than previously 
reported concentrations that maybe due to sample and dosage 
differences.
The PKs of enrofloxacin in the infected and healthy models 
were quite different. Higher AUC was obtained in infected 
broilers (406.7 μg h/mL) when compared to healthy (206.3 μg h/
FigUre 5 | TheEx vivo inhibition curve in the intestinal content from healthy chicken (a) and infected chicken (B). The X-axis was the time point during 
the 24-hours incubation and Y-axis was the bacterial number under exposure to intestinal samples collected from different time point in the PK study.
TaBle 4 | PK/PD parameter of ex vivo data after oral administration 
enrofloxacin in chicken.
Parameter Unit healthy infected
Emax Log10CFU/mL 2.35 2.91
E0 Log10CFU/mL −5.62 −5.69
Emax−E0 Log10CFU/mL 7.97 8.60
EC50 h 348.51 802.26
Slope (N) – 2.85 2.72
AUC24/MIC for bacteriostatic 
action (E = 0)
h 258.73 624.94
AUC24/MIC for bactericidal  
action (E = −3)
h 451.35 1065.93
AUC24/MIC for bacterial 
eradication (E = −4)
h 567.39 1343.81
TaBle 5 | The different dosages (milligram per kilogram) when Mic of 
enrofloxacin is 0.5 μg/ml.
effect (E) healthy dosage infected dosage
Bacteriostatic action (E = 0) 5.6 7.0
Bactericidal action (E = −3) 9.8 11.9
Bacterial eradication (E = −4) 12.4 15.1
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mL) broilers. The differences of the PKs in healthy and infected 
broilers maybe due to the changes of the physiological and bio-
chemical indexes, such as the change in their body temperature, 
the decrease of the protein in plasma, decline of blood pressure, 
anemia, liver dysfunction by acetylation, and so on. The PK 
parameter in diseased animals is much similar to clinical condi-
tions. As previous research has shown, the metabolic conversion 
of enrofloxacin to ciprofloxacin is quite different in different 
animal species for example: 59% in dairy cows, 36% in sheep, 
47% in buffalo calves, and 64% in beef steers (32–34).
In this study, the ratio of ciprofloxacin AUC (31.39) and 
enrofloxacin AUC (406.74) is 7.71% after oral administration 
in infected broilers. Differing from other animal species, the 
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FigUre 7 | The pharmacokinetic change (a) and pharmacodynamic change (B) under 3-day treatment simulated by mlxplore software. Adm1, 2, and 
3 represented 3-day daily-treatment with 7,11.9, and 15.1 mg/kg enrofloxacin, respectively.
FigUre 6 | The pharmacokinetic change (a) and pharmacodynamic change (B) under 1-day single treatment simulated by mlxplore software. Adm1, 
2, and 3 represented 1-day single treatment with 7.0, 11.9, and 15.1 mg/kg enrofloxacin, respectively.
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TaBle 6 | The growth of resistant strains after exposed to different drug concentrations.
Time (h) B 0.125 0.25 0.5 1 2 4 8
2 N N N N N N N N
4 N N N N N N N N
6 N N N N N N N N
8 + N + N N N N N
12 + + N N + N N N
18 + N + N + + N N
24 ++ ++ + ++ N + N N
36 ++ ++ ++ + N ++ ++ N
48 ++ ++ ++ ++ + ++ ++ N
B, the blank group.
N, colony number below 10 CFU/mL.
+, colony number between 10 and 100 CFU/mL.
++, colony number beyond 100 CFU/mL.
TaBle 7 | The therapeutic effect of enrofloxacin against colibacillosis.
group Bacterial concentration sum chickens Dead chickens Protection rate
Test 8 mL,109 CFU/mL 11.9 mg/kg BW 12 2 83.3%
Control 8 mL,109 CFU/mL No treatment 12 11 8.3%
biotransformation of enrofloxacin to ciprofloxacin in poultry is 
limited to only 5–10%, and the ciprofloxacin concentrations are 
always below the LOQ. (23, 35, 36). The metabolite ciprofloxacin 
usually has antimicrobial activity, so it is quite important to evalu-
ate the combined action of the enrofloxacin and ciprofloxacin 
(37). As such, the sum of the concentrations of two drugs should 
be evaluated by the PK/PD integration and modeling.
The MIC results suggest a bimodal distribution and the 349 
strains with MIC ranging between 1 and 64 μg/mL indicates the 
high increase of antibiotic resistance. Compared to other stud-
ies on APEC and AFEC strains (38), 28.5% strains with MIC 
between 0.5 and 1 μg/mL were considered intermediately resist-
ant, confirming the trend of increasing resistance. In recent years, 
it has been suggested that the optimization of dosing regimen not 
only for the treatment but also for reducing antimicrobial resist-
ance development. MIC is used as an in vitro reference value to 
predict the antimicrobial efficacy and potency of a drug. The MIC 
values in broth and biological fluids reported in previous research 
(39) shows that the serum inhibitory activity is reduced for most 
fluoroquinolones. In this study, the MIC values of the pathogen 
E. coli (Auihui 112) for enrofloxacin in intestinal contents and 
broth both are 0.25 μg/mL, which indicates that enrofloxacin has 
the same antimicrobial activity in broth and intestinal contents. 
In our study, the in vitro and ex vivo time-kill curves indicate that 
enrofloxacin rapidly eliminates E. coli. Rapid inhibition and kill-
ing of bacteria exhibited by ex vivo inhibition curves is consistent 
with in  vitro time-kill data and the previous studies published 
for danofloxacin and marbofloxacin (39, 40). The time-kill curves 
seem to indicate that enrofloxacin is concentration dependent. 
The data from the current study show that bacterial counts will 
increase after 24-h incubation a time when the antibiotic concen-
tration is lower. These data confirms findings in previous publica-
tions stating that MIC alone does not offer enough information 
about the efficacy of therapy (21).
Enrofloxacin shows a concentration-dependent killing activ-
ity like other fluoroquinolone drugs (41). The main PK/PD 
parameters for concentration-dependent antimicrobials are Cmax/
MIC and AUC/MIC, the AUC/MIC ratio is a more important 
surrogate for the PK/PD analysis (42).
The breakpoint of Cmax/MIC ≥ 10 and AUC24/MIC ≥ 125 is an 
indicator for the success of therapy and preventing the emergence 
of resistance of fluoroquinolones (43). In vivo AUC24/MIC50 are 
455.20 and 887.41, respectively, for healthy and infected broil-
ers at the dosage of 10 mg/kg. The values of ex vivo AUC/MIC 
obtained for bactericidal action in intestinal contents from 
healthy and infected broilers is 451.35 and 1065.93, respectively. 
The enrofloxacin concentrations in intestine are detected in much 
higher concentrations than in plasma; which would potentially 
lead to an eradication of the E. coli in intestine. In this study, 
based on the MIC50 = 0.5 μg/mL, values of Cmax/MIC (43.12) and 
AUC24/MIC (455.20) both values exceed the predictive effective 
values. These values are comparable with the values of Cmax/MIC 
(38) and AUC24/MIC (293) obtained from buffalo calves (44).
Pharmacokinetic/pharmacodynamic modeling serves as 
a bridge between PK and PD and has been considered as a 
promising approach (4, 8, 20). Results obtained from this study 
based on the PK/PD integration suggest that when the MIC50 of 
enrofloxacin is 0.5  μg/mL, for bacteriostasis, bactericidal, and 
bacterial eradication in infected broilers, the dosage should be 7.0, 
11.9, and 15.1 mg/kg BW., respectively. Results from professional 
software used to simulate different dosage regimens for treatment 
show that a 3-day treatment of 11.9 mg/kg every 24 h should be 
efficient against E. coli (Anhui 112) in broilers. Therefore, the dose 
of 11.9 mg/kg BW. should be effective for treating colibacillosis 
when the MIC ≤ 0.5 μg/mL.
Antimicrobial resistance is a principal threat for both animals 
and humans. Using PK/PD modeling choosing an appropriate 
therapeutic schedule is a suitable strategy to reduce antimicrobial 
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